natgillin/translations-raw huggingface dataset:
The first study included patients whose cancer came back 6 months or more after previous treatment (‘platinum-sensitive disease’), while the second study was in patients with more aggressive cancer that had come back within 6 months of previous treatment (‘platinum-resistant disease’).
V prvo študijo so vključili bolnike, pri katerih se je rak ponovno pojavil šest ali več mesecev po predhodnem zdravljenju („bolezen, občutljiva za platino“), v drugi študiji pa so sodelovali bolniki z agresivnejšo obliko raka, ki se je ponovno pojavil v šestih mesecih po predhodnem zdravljenju („bolezen, odporna proti platini“).
The first study investigated the effects of Esmya compared with placebo (a dummy treatment) in adult women with heavy uterine bleeding and anaemia.
V prvi študiji so učinke zdravila Esmya primerjali z učinki placeba (zdravila brez zdravilne učinkovine) pri odraslih ženskah z močno krvavitvijo iz maternice in anemijo.
The first study involved 1,195 men with metastatic prostate cancer whose disease had got worse despite surgical or medical castration treatment and chemotherapy with docetaxel.
V prvo študijo je bilo vključenih 1 195 moških z metastatskim rakom prostate, katerih bolezen se je poslabšala kljub kirurški ali kemični kastraciji in kemoterapiji z docetakselom.
The first study involved 1,663 patients whose diabetes was not adequately controlled with the diabetes medicines metformin or metformin and pioglitazone taken by mouth; adding Xultophy to their treatment was compared with adding either of its active substances, insulin degludec or liraglutide.
Dodajanje zdravila Xultophy njihovemu zdravljenju so primerjali z dodajanjem ene od obeh zdravilnih učinkovin, bodisi insulina bodisi liraglutida.
The first study involved 17 patients with aHUS who did not respond to or could not be treated with plasma exchange or infusion.
Prva študija je vključevala 17 bolnikov s to boleznijo, ki se niso odzvali na izmenjavo plazme ali infuzijo ali jih niso mogli tako zdraviti.
The first study involved 2,046 patients with breast cancer.
V prvo študijo je bilo vključenih 2 046 bolnic z rakom dojke.
The first study involved 22 patients aged 12 years and above, who were given Nuwiq for the treatment of bleeding episodes or to prevent bleeding during surgery.
V prvi študiji je sodelovalo 22 bolnikov, starih 12 let ali več, ki so jim dajali zdravilo Nuwiq za zdravljenje krvavitev ali za preprečevanje krvavitve med kirurškim posegom.
The first study involved 327 previously untreated patients who were infected with hepatitis C virus of genotypes 1, 4, 5 or 6, and who were given Sovaldi together with two other antiviral medicines, peginterferon alfa and ribavirin, for 12 weeks.
V prvi študiji je sodelovalo 327 predhodno nezdravljenih bolnikov, okuženih z virusom hepatitisa C genotipa 1, 4, 5 ali 6, ki so 12 tednov prejemali zdravilo Sovaldi v kombinaciji z dvema drugima protivirusnima zdraviloma, peginterferonom alfa in ribavirinom.
The first study involved 35 patients who were given one injection of Ilaris which was repeated after eight weeks.
V prvi študiji je sodelovalo 35 bolnikov, ki so najprej prejeli eno injekcijo zdravila Ilaris, drugo pa osem tednov kasneje.
The first study involved 37 patients and response to treatment was defined as elimination of at least 90% of the giant cells or no progression of the condition after 25 weeks of treatment.
V prvo študijo je bilo vključenih 37 bolnikov, odziv na zdravljenje pa je bil opredeljen kot uničenje vsaj 90 % gigantskih celic ali nenapredovanje bolezni po 25 tednih zdravljenja.
The first study involved 40 previously untreated patients with type-1 Gaucher disease, and it looked mainly at the reduction in the size of patients’ spleens.
V prvi študiji, v kateri je sodelovalo 40 predhodno nezdravljenih bolnikov z Gaucherjevo boleznijo tipa 1, so proučevali predvsem zmanjšanje velikosti vranice pri bolnikih.
the first study involved 424 patients with locally advanced cancer, looking at the effects of adding Erbitux to radiotherapy; the second study involved 442 patients with recurrent or metastatic cancer, looking at the effects of adding Erbitux to a platinum-based anticancer medicine combination.
v prvo študijo, v kateri so proučevali učinke dodajanja zdravila Erbitux med obsevanjem, je bilo vključenih 424 bolnikov z lokalno napredovalnim rakom; v drugo študijo je bilo vključenih 442 bolnikov s ponavljajočim se ali metastatskim rakom, v njej pa so proučevali učinke dodajanja zdravila Erbitux kombinaciji zdravil proti raku na osnovi platine.
The first study involved 616 adults and adolescents given Nucala every 4 weeks for a year, in addition to their regular asthma medicines.
Prva študija je zajela 616 odraslih in mladostnikov, ki so poleg svojih rednih zdravil za astmo prejemali zdravilo Nucala enkrat na štiri tedne v obdobju enega leta.
The first study involved 63 patients whose spleens had been removed but whose disease was still not controlled.
Prva študija je vključevala 63 bolnikov, ki so jim odstranili vranico, vendar s tem niso uspeli nadzorovati bolezni.
The first study involved 724 patients with hormone receptor-positive and HER2/neu-negative advanced breast cancer which had got worse after treatment with letrozole and anastrazole (‘non-steroidal aromatase inhibitors’ cancer medicines).
Prva študija je vključevala 724 bolnikov z napredovalim rakom dojke, ki je bil pozitiven na hormonske receptorje in negativen na HER2/neu ter se je poslabšal po zdravljenju z letrozolom in anastrazolom (zdraviloma za zdravljenje raka, ki spadata med „nesteroidne zaviralce aromataze“).
The first study involved 835 adults aged 50 to 64 years who had not previously been vaccinated against invasive disease caused by
V prvi študiji je sodelovalo 835 odraslih, starih od 50 do 64 let, ki predhodno niso bili cepljeni proti invazivni bolezni, ki jo povzroča bakterija S. pneumoniae.
The first study involved 86 adults with short bowel syndrome due to removal of a large section of the small intestine and who needed parenteral nutrition (nutrients and fluids given directly into a vein) at least three times a week.
V prvo študijo je bilo vključenih 86 bolnikov s sindromom kratkega črevesa zaradi odstranitve velikega dela tankega črevesa, ki so potrebovali parenteralno prehrano (hranilne snovi in tekočina se dajejo neposredno v veno) vsaj trikrat tedensko.
The first study involved a total of 2,101 patients who had had a knee replacement operation, and the second involved a total of 3,494 patients who had had a hip replacement.
V prvo študijo je bil vključen 2 101 bolnik, ki so mu operativno vstavili umetno koleno, v drugo pa 3 494 bolnikov, ki so jim operativno vstavili umetni kolk.
The first study involved a total of 70 children and young adults aged below 21 years, and the second involved a total of 40 adults and adolescents aged over 16 years.
V prvo študijo je bilo vključenih 70 otrok in mladih, starih do 21 let, v drugo pa 40 odraslih in mladostnikov, starejših od 16 let.
The first study involved patients whose disease was not controlled with high doses of corticosteroids.
V prvo študijo so bili vključeni bolniki, pri katerih bolezen ni bila nadzorovana z velikimi odmerki kortikosteroidov.
The first study involving 418 previously untreated advanced melanoma patients found that patients treated with Opdivo survived longer than patients who received the cancer medicine dacarbazine: 73% of patients treated with Opdivo were alive at 12 months compared with 42% of patients given dacarbazine.
V prvi študiji, ki je proučevala 418 predhodno nezdravljenih bolnikov z napredovalim melanomom, so ugotovili, da so bolniki, ki so se zdravili z zdravilom Opdivo, živeli dlje kot tisti, ki so jemali zdravilo za zdravljenje raka dakarbazin: 73 % bolnikov, zdravljenih z zdravilom Opdivo, je bilo po dvanajstih mesecih še živih v primerjavi z 42 % tistih, ki so prejemali dakarbazin.
The first study showed that Relvar Ellipta 92/22 microgram improved average FEV1 by 115 ml more than placebo, while the second study showed that Relvar Ellipta 184/22 microgram improved average FEV1 by 131 ml more than placebo.
V prvi študiji so zabeležili, da je zdravilo Relvar Ellipta 92/22 mikrogramov izboljšalo povprečni FEV1 za 115 ml več kot placebo, medtem ko so v drugi študiji zabeležili, da je zdravilo Relvar Ellipta 184/22 mikrogramov izboljšalo povprečni FEV1 za 131 ml več kot placebo.
The first study showed that Revinty Ellipta 92/22 microgram improved average FEV1 by 115 ml more than placebo, while the second study showed that Revinty Ellipta 184/22 microgram improved average FEV1 by 131 ml more than placebo.
V prvi študiji so zabeležili, da je zdravilo Revinty Ellipta 92/22 mikrogramov izboljšalo povprečni FEV1 za 115 ml več kot placebo, medtem ko so v drugi študiji zabeležili, da je zdravilo Revinty Ellipta 184/22 mikrogramov izboljšalo povprečni FEV1 za 131 ml več kot placebo.
The first study was in 5,407 patients who had undergone a hip replacement.
Prva študija je bila izvedena pri 5 407 bolnikih, ki so jim operativno vstavili umetni kolk.
The first symptoms of low blood sugar usually come on quickly and include the following:
Prvi simptomi nizkega krvnega sladkorja se običajno pojavijo hitro in vključujejo naslednje:
The first symptoms usually appear within three months of the start of therapy with a rash as the most common adverse reaction followed by fever and much less frequently by gastrointestinal disturbances of anorexia, nausea or diarrhoea.
Prvi simptomi se običajno pojavijo v treh mesecih od začetka zdravljenja, pri čemer se najpogosteje pojavi izpuščaj, ki mu sledijo zvišana telesna temperatura in precej manj pogosto prebavne motnje, kot so anoreksija, navzea in driska.
The first symptoms which alert you to hypoglycaemia ("warning symptoms") may change, be weaker or may be missing altogether if
Prvi simptomi, ki opozarjajo na hipoglikemijo ("opozorilni simptomi"), se lahko spremenijo, oslabijo ali jih celo sploh ni več, če
The first symptoms which alert you to hypoglycaemia ("warning symptoms") may change, be weaker or may be missing altogether if
Prvi simptomi, ki opozarjajo na hipoglikemijo ("opozorilni simptomi"), se lahko spremenijo, oslabijo ali jih celo sploh ni več:
The first symptoms which alert you to hypoglycaemia ("warning symptoms") may change, be weaker or may be missing altogether if:
Prvi simptomi, ki opozarjajo na hipoglikemijo ("opozorilni simptomi"), se lahko spremenijo, oslabijo ali jih celo sploh ni več, če
The first symptoms which alert you to hypoglycaemia ("warning symptoms") may change, be weaker or may be missing altogether if:
Prvi simptomi, ki opozarjajo na hipoglikemijo ("opozorilni simptomi"), se lahko spremenijo, oslabijo ali jih celo sploh ni več, če:
The first symptoms which alert you to hypoglycaemia (“warning symptoms”) may change, be weaker or may be missing altogether if
Prvi simptomi, ki opozarjajo na hipoglikemijo ("opozorilni simptomi"), se lahko spremenijo, oslabijo ali jih celo sploh ni več, če
The first symptoms which alert you to hypoglycaemia (“warning symptoms”) may change, be weaker or may be missing altogether if:
Prvi simptomi, ki vas opozorijo na hipoglikemijo (“opozorilni simptomi”), se lahko spremenijo, oslabijo ali sploh ne nastopijo, če:
The first tablet Tasmar is to be taken in the morning together with your other parkinsonian medicine ‘levodopa’.
Prvi odmerek zdravila Tasmar se vzame s prvim dnevnim odmerkom vašega drugega zdravila za zdravljenje Parkinsonove bolezni, ki vsebuje levodopo.
The first time you use ANORO you do not need to check that the inhaler is working properly; it contains previously measured doses and is ready to use straight away.
Ko zdravilo ANORO uporabite prvič, vam ni treba preverjati, ali inhalator deluje pravilno; inhalator vsebuje predhodno odmerjene odmerke zdravila in je pripravljen za takojšnjo uporabo.
The first time you use Incruse you do not need to check that the inhaler is working properly; it contains previously measured doses and is ready to use straight away.
Ko zdravilo Incruse prvič uporabite, vam ni treba preverjati, ali inhalator deluje pravilno; inhalator vsebuje predhodno odmerjene odmerke in je pripravljen za takojšnjo uporabo.
The first time you use LAVENTAIR you do not need to check that the inhaler is working properly; it contains previously measured doses and is ready to use straight away.
Ko zdravilo LAVENTAIR uporabite prvič, vam ni treba preverjati, ali inhalator deluje pravilno; inhalator vsebuje predhodno odmerjene odmerke zdravila in je pripravljen za takojšnjo uporabo.
The first treatment course, given open label, resulted in a complete clearance rate of 62% (277/450).
V prvem ciklu zdravljenja, ki je bil odprt, so dosegli 62- odstotno stopnjo popolne ozdravitve (277/450).
The first treatment course, given open label, resulted in a complete clearance rate of 62% (277/450).
V prvem krogu zdravljenja, ki je bil odprt, so dosegli 62- odstotno stopnjo popolne ozdravitve (277/450).
The first treatment is then consolidated, three to four weeks later, by giving Trisenox once a day for five days, followed by a two-day break, repeated for five weeks.
Prvo zdravljenje se nato utrdi tri do štiri tedne kasneje tako, da se zdravilo Trisenox daje pet dni zaporedoma enkrat dnevno, čemur sledi dvodnevni premor, kar se ponavlja pet tednov.
The first two numbers indicate the month; the next four numbers indicate the year.
Prvi dve številki pomenita mesec; naslednje štiri številke pomenijo leto.
The first two studies included a total of 991 patients who had not had an adequate response to methotrexate in the past, and the third included 391 patients who had not had an adequate response to TNF blockers in the past.
Prvi študiji sta vključevali skupno 991 bolnikov, ki se v preteklosti niso ustrezno odzvali na metotreksat, tretja pa je vključevala 391 bolnikov, ki se v preteklosti niso ustrezno odzvali na zaviralce TNF.
The first two studies involved patients whose metastatic disease was being treated for the first time (‘first-line’ treatment): the first study (in 923 patients) and the second study (in 1,401 patients) compared Avastin with placebo (a dummy treatment) when given in combination with chemotherapy.
V prvo študijo so bili vključeni bolniki, katerih metastatska bolezen je bila zdravljena prvič (zdravljenje „prve izbire“): v prvi (pri 923 bolnikih) in drugi študiji (pri 1 401 bolniku) so primerjali zdravilo Avastin s placebom (zdravilom brez zdravilne učinkovine), kadar se daje s kemotarepijo.
The first vaccine dose can be injected on the same day as human hepatitis B immunoglobulin, however in different sites.
Prvi odmerek cepiva se lahko uporabi isti dan kot človeški imunoglobulin proti hepatitisu B, vendar na drugem predelu telesa.
The first ‘click’ means that the needle has been inserted and the injection has started.
Prvi ‘klik’ pomeni, da je igla vstavljena in da se je injiciranje pričelo.
The first, an 8-week, placebo controlled trial conducted in adult patients (n=404) who were experiencing acute psychotic symptoms.
Prvo, 8-tedensko, s placebom nadzorovano preskušanje so opravili pri odraslih bolnikih (n=404), ki so imeli akutne psihotične simptome.
The five studies on the effects of saxagliptin alone or in combination with metformin also showed that adding saxagliptin to metformin was effective in lowering HbA1c levels.
Pet študij o učinkih saksagliptina, uporabljenega samostojno ali v kombinaciji z metforminom, je ravno tako pokazalo, da je dodajanje saksagliptina metforminu učinkovito pri zniževanju ravni HbA1c.
The flange of the transfer device should rest on the surface of the stopper so that the solvent flows into the powder vial.
Prirobnica pripomočka za prenos naj počiva na površini zamaška, da vehikel steče v vialo s praškom.
The flea field study found a 90% reduction in flea count in 96.7% and 88.7% of Trifexis-treated dogs at day 14 and 30 respectively, compared with 85.9% and 73.2% in the selamectin-treated dogs.
V terenski študiji bolh so na 14. dan zabeležili 90-odstotno zmanjšanje števila bolh pri 96,7 % psov, ki so prejemali zdravilo Trifexis, na 30. dan pa pri 88,7 % psov.
The flea life cycle is broken due to the rapid onset of action and long lasting efficacy against adult fleas on the animal and the absence of viable egg production.
Življenjski cikel bolhe je prekinjen zaradi hitrega začetka delovanja in dolgo trajajočega učinkovanja proti odraslim bolham na psu in ker bolhe ne proizvajajo več za življenje sposobnih jajčec.
The flea preventive effect against re-infestations is a result of the adulticidal activity and the reduction in egg production and persists for up to 4 weeks after a single administration of the veterinary medicinal product.
Učinek preprečevanja ponovnih infestacij z bolhami je rezultat insekticidnega delovanja na odrasle oblike in zmanjšanja količine njihovih jajčec, ki se po enem dajanju zdravila ohrani do 4 tedne.
The flea preventive effect against re-infestations is a result of the adulticidal activity and the reduction in egg production and persists for up to 4 weeks after a single administration of this product.
Učinek preprečevanja ponovnih infestacij z bolhami je rezultat insekticidnega delovanja na odrasle oblike in zmanjšanja tvorbe jajčec, ki se po dajanju zdravila ohrani do 4 tedne.
The flow of charged particles in and out of the muscle cells produces the excessive electrical activity that leads to atrial fibrillation and rapid heart rate.
Tok nabitih delcev v mišične celice in iz njih privede do prekomernega električnega delovanja, ki povzroči atrijsko fibrilacijo in pospešeni srčni utrip.
The fluctuation index (FI), a measure of the relative difference between peak and trough concentrations ((Cmax-Cmin)/Cavg), was 0.58 for Prometax 4.6 mg/24 h transdermal patches, 0.77 for Prometax
Fluktuacijski indeks(FI), ki izraža relativno razliko med najvišjimi in najnižjimi koncentracijami ((Cmax-Cmin)/Cavg; pri tem je Cavg povprečna koncentracija v obdobju odmerjanja), je bil 0,58 pri transdermalnih obližih Prometax 4,6 mg/24 h, 0,77 pri transdermalnih obližih Prometax 9,5 mg/24 h in 0,72 pri transdermalnih obližih Prometax
The fluoroquinolones exert their antibacterial effect against both replicating and dormant micro- organisms.
Fluorokinoloni imajo protimikrobno učinkovanje tako proti mikroorganizmom, ne glede na to, ali so v fazi replikacije ali ne.
The fluoroquinolones exert their antibacterial effect against both replicating and non-replicating micro-organisms.
Fluorokinoloni imajo protimikrobno učinkovanje tako proti mikroorganizmom, ki so v fazi replikacije, kot tistim, ki niso v tej fazi.
The fluoroquinolones exert their antibacterial effects against both replicating and dormant micro- organisms.
Fluorokinoloni imajo protimikrobno učinkovanje tako proti mikroorganizmom, ki so v fazi replikacije, kot tistim, ki so v fazi transkripcije pri delitvi celic.
The foil sachets are packaged in an outer carton.
Vrečica iz folije je pakirana v zunanjo škatlo.
The foil sachets are packaged in an outer carton.
Vrečka iz folije je pakirana v zunanjo škatlo.
The folding box contains one vial with a lyophilised powder, one ready for use syringe with a solvent, one vial adapter and one needle.
Škatla vsebuje eno vialo z liofiliziranim praškom, eno brizgo z vehiklom, pripravljeno za uporabo, en adapter za vialo in eno iglo.
The follitropin alfa in Bemfola, as well as in the reference product GONAL-f, is produced by a method known as ‘recombinant DNA technology’: it is made by cells into which a gene (DNA) has been introduced, which makes them able to produce human FSH.
Folitropin alfa v zdravilu Bemfola in referenčnem zdravilu GONAL-f pa proizvajajo z metodo, znano kot „tehnologija rekombinantne DNK“, pri kateri so v celice vstavili gen (DNK), s katerim lahko te tvorijo humani FSH.
The follitropin alfa in Ovaleap, as well as in the reference product GONAL-f, is produced by a method known as ‘recombinant DNA technology’: it is made by cells into which a gene (DNA) has been introduced that makes them able to produce human FSH.
Folitropin alfa v zdravilu Ovaleap in tudi v zdravilu GONAL-f se pridobiva z metodo, imenovano „tehnologija rekombinantne DNA“, pri kateri je v celice vstavljen gen (DNK), s katerim lahko tvorijo humani FSH.
The follitropin beta in Fertavid is produced by a method known as ‘recombinant DNA technology’: it is made by a cell that has received a gene (DNA), which makes it able to produce human FSH.
Folitropin beta, ki ga vsebuje zdravilo Fertavid, je pridobljen z metodo, imenovano „tehnologija rekombinantne DNK“,. pri kateri celica prejme gen (DNK), s katerim lahko tvori humani FSH.
The follitropin beta in Puregon is produced by a method known as ‘recombinant DNA technology’.
Folitropin beta, ki ga vsebuje zdravilo Puregon, je pridobljen z metodo, znano kot „tehnologija rekombinantne DNK“.
The following actions have been demonstrated for endogenous human IGF-1:
Dokazani so bili naslednji učinki endogenega humanega IGF-1:
The following active substances may affect the heart rhythm:
Naslednje zdravilne učinkovine lahko vplivajo na srčni ritem:
The following active substances may increase the risk of side effects with Bosulif:
Naslednje zdravilne učinkovine lahko povečajo tveganje za pojav neželenih učinkov pri jemanju zdravila Bosulif:
The following active substances may reduce the effectiveness of Bosulif:
Naslednje zdravilne učinkovine lahko zmanjšajo učinkovitost zdravila Bosulif:
The following active substances should not be administered simultaneously through the same Y-site as tigecycline: Amphotericin B, amphotericin B lipid complex, diazepam, esomeprazole, omeprazole and intravenous solutions that could result in an increase of pH above 7.
Naslednjih zdravilnih učinkovin ni dovoljeno injicirati sočasno skozi isti podaljšek Y kot tigeciklin: amfotericin B, amfotericin B v obliki lipidnega kompleksa, diazepam, esomeprazol, omeprazol in intravenske raztopine, ki bi lahko povzročile zvišanje pH nad 7.
The following activities should be avoided:
Izogibati se je treba sledečim aktivnostim:
The following additional adverse events were reported from post-marketing surveillance with seasonal non-adjuvanted trivalent vaccines in all age groups and an MF59 seasonal adjuvanted trivalent vaccine with a composition similar to Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics (surface antigen, inactivated, adjuvanted with MF59C.1) that is licensed for use in elderly subjects 65 years of age and older:
Iz spremljanja v obdobju trţenja so poročali o naslednjih neţelenih učinkih s sezonskimi trivalentnimi cepivi brez adjuvansov v vseh starostnih skupinah in pri sezonskem trivalentnem cepivu MF59 z adjuvansom s podobno sestavo kot jo ima cepivo Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics (s površinskimi antigeni, inaktivirano, z adjuvansom MF59C.1), ki je odobren za uporabo pri osebah, starih več kot 65 let:
The following additional adverse reaction has been observed in a study of patients with dementia associated with Parkinson’s disease treated with Exelon transdermal patches: agitation (common).
Naslednji neželeni učinek so, poleg že navedenih, opažali v študiji pri bolnikih, ki so imeli demenco v povezavi s Parkinsonovo boleznijo in so bili zdravljeni s transdermalnimi obliži Exelon: agitiranost (pogosti).
The following additional adverse reaction has been observed in a study of patients with dementia associated with Parkinson’s disease treated with Prometax transdermal patches: agitation (common).
Naslednji neželeni učinek so, poleg že navedenih, opažali v študiji pri bolnikih, ki so imeli demenco v povezavi s Parkinsonovo boleznijo in so bili zdravljeni s transdermalnimi obliži Prometax: agitiranost (pogosti).
The following additional adverse reaction has been observed in a study of patients with dementia associated with Parkinson’s disease treated with rivastigmine transdermal patches: agitation (common).
Naslednji neželeni učinek so, poleg že navedenih, opažali v študiji pri bolnikih, ki so imeli demenco v povezavi s Parkinsonovo boleznijo in so bili zdravljeni s transdermalnimi obliži z rivastigminom: agitiranost (pogosti).